Suzhou CStone Pharma out-licensed greater China rights for its CTLA-4 mAb to Jiangsu Hengrui Pharma in a $200 million agreement. Hengrui will have rights to develop, manufacture and commercialize CS1002 in the territories. CStone has completed a successful China Phase I trial of CS1002 in combination with its PD-1 that enrolled patients with melanoma, hepatocellular carcinoma and microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) tumors. The company will receive up to $200 million in upfront and milestone payments, plus double-digit royalties from Hengrui. More details.... Stock Symbols:  (HK: 2616) (SHA: 600276) Share this with colleagues: // //